Active Filter(s):
Details:
Medytox applied for a license for Meditoxin (export name: Neuronox having Clostridium Botulinum Toxin type A), Medytox’s BTX product, to China’s National Medical Products Administration in February 2018.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Neurology Product Name: Neuronox
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Bloomage Biotechnology Corp., Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination August 04, 2022
Details:
The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.
Lead Product(s): COVAX-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Recipient: Vaxine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 25, 2020